PharmiWeb.com - Global Pharma News & Resources

Press Releases

Date Title Company
10-Apr-2025 Lab Innovations claims top event award Lab Innovations
10-Apr-2025 Next expansion milestone achieved: SCHOTT Pharma opens production facility in Serbia to strengthen competitiveness in Europe SCHOTT Pharma AG & Co. KGaA
10-Apr-2025 Siegfried shareholders approve all proposals at Annual General Meeting 2025 Siegfried AG
10-Apr-2025 Phastar Secures Finalist Spot at 2025 Citeline Awards Phastar
10-Apr-2025 Revolutionizing Animal Healthcare: Veterinary Telemedicine Market on a Robust Growth Trajectory MARKITWIRED
10-Apr-2025 Eckert & Ziegler: US Consul Visits Radiopharmaceutical Production in Braunschweig Eckert & Ziegler SE
10-Apr-2025 Recreational Oxygen Equipment Market: Breathing New Life into Wellness and Fitness Ameco Research
10-Apr-2025 Molecular Diagnostics Market Set to Soar, Expected to Reach USD 71.1 Billion by 2035 Vantage Market Research
10-Apr-2025 Viromed Medical AG: Exclusive distribution partnership with AMAMUS Vet for the cold plasma medical device ViroCAP® VET for veterinary use Viromed Medical AG
10-Apr-2025 SFWJ / Medcana Announces it is Canceling over 80 Million Shares ACCESS Newswire
10-Apr-2025 Cellistic Launches Echo™ – NK Platform, a Scalable Solution for Off-the-Shelf Allogeneic Immune Cell Therapies Cellistic
10-Apr-2025 Microsurgery Market Set to Surpass USD 5.07 Billion by 2035 | VMR Vantage Market Research
10-Apr-2025 CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update CureVac
10-Apr-2025 Travel Nurses, Inc. Launches Industry Newsletter on LinkedIn ACCESS Newswire
10-Apr-2025 Cancer Immunotherapy Market Size | USD 294.4 Bn & CAGR 8.40% Growth By 2035 Vantage Market Research
10-Apr-2025 Projected Growth of Injectable Drug Delivery Market to USD 1808.5 Billion by 2035 Vantage Market Research
10-Apr-2025 Coulter Partners strengthens leadership at iOnctura with placement of Board Chair Coulter Partners
10-Apr-2025 Black Book Research Announces 2025 Top-Rated Payer Enterprise Analytics Vendors Based on Client Satisfaction Scores ACCESS Newswire
10-Apr-2025 Evotec SE to announce results for financial year 2024 on 17 April 2025 Evotec SE
10-Apr-2025 NICE recommends BALVERSA®▼ (erdafitinib), the first and only treatment in the UK for metastatic or unresectable fibroblast growth factor receptor (FGFR3)-altered urothelial cancer (UC) for patients who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor Johnson & Johnson